1. Home
  2. MRLN vs IPHA Comparison

MRLN vs IPHA Comparison

Compare MRLN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merlin Inc. Common Stock

MRLN

Merlin Inc. Common Stock

N/A

Current Price

$1.36

Market Cap

172.8M

Sector

Technology

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.48

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MRLN
IPHA
Founded
2018
1999
Country
United States
France
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.8M
165.3M
IPO Year
2024
2014

Fundamental Metrics

Financial Performance
Metric
MRLN
IPHA
Price
$1.36
$1.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
★ $8.58
$6.67
AVG Volume (30 Days)
★ 3.3M
51.1K
Earning Date
11-15-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$9.23
$390.56
Revenue Next Year
$153.29
$143.06
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$1.18
52 Week High
$17.00
$2.71

Technical Indicators

Market Signals
Indicator
MRLN
IPHA
Relative Strength Index (RSI) 25.23 26.64
Support Level N/A $1.34
Resistance Level $3.45 $1.57
Average True Range (ATR) 0.17 0.09
MACD -0.01 -0.02
Stochastic Oscillator 8.92 0.00

Price Performance

Historical Comparison
MRLN
IPHA

About MRLN Merlin Inc. Common Stock

Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: